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Aims. Antenatal dexamethasone administration for fetal lung development may impair maternal glucose tolerance. In this study,
we investigated whether glucose and insulin levels diﬀered among singleton and twin pregnancies and pregnancies with impaired
glucose tolerance (IGT) after treatment with dexamethasone. Methods. Singleton pregnancies, twin pregnancies, and pregnancies
with IGT between 28 and 33 weeks of gestation whose mothers were treated with dexamethasone were enrolled in this study.
Exclusion criteria included gestational hypertension, diabetes, renal disorders, and infectious diseases. The fasting plasma glucose
and insulin levels were checked before administration and 24h, 48h, and 72h after treatment was completed. Results. Mean
glucose levels were signiﬁcantly higher in the twin pregnancy and IGT groups at 24h and 48h after the administration of
dexamethasone than those in the singleton pregnancy group (P<0.05). Although there was no signiﬁcant diﬀerence in glucose
levels before administration and 72h after dexamethasone administration among the three groups, insulin levels in the IGT
group were signiﬁcantly higher (P<0.05). Insulin levels in the singleton pregnancy group at 24h and 48h after treatment were
signiﬁcantly lower than in the twin and IGT groups. Conclusion. The eﬀects on maternal fasting blood glucose and insulin levels
of dexamethasone administrated to promote fetal lung maturation correlated with embryo number and the presence of IGT.
1.Introduction
The most common cause of deaths among preterm babies
is respiratory distress syndrome (RDS); antenatal corti-
costeroid (ACS) treatment for pregnant women at risk
of preterm birth is an established intervention for the
prevention of RDS. Liggins and Howie ﬁrst described this
indication in 1972, when they demonstrated that ACS could
reduce the risk of neonatal RDS from 25.8% to 9.0%,
and the rate of neonatal mortality dropped from 15.0% to
3.2% [1, 2]. In 1994, a National Institutes of Health (NIH)
consensus conference recommended that women at risk of
preterm birth before 34 weeks of gestation, who delivered
within 7 days, should routinely be given a course of ACS
[3]. Since then, the incidence and mortality rates of RDS,
intraventricularhemorrhage,andnecrotizingenterocolitisin
preterm infants have been signiﬁcantly reduced.
However, corticosteroid therapy has some adverse mater-
nal eﬀects, including adrenal suppression and altered glu-
cose tolerance [4]. Mathiesen [5] reported that diabetic
mothers receiving glucocorticoid treatment for fetal lung
maturation may have poor glycemic control and need to
adjust insulin usage. To what extend short-term use of
corticosteroids for fetal lung maturation aﬀects fasting blood
glucose and insulin levels in normal singleton pregnancies,
normal twin pregnancies, and IGT pregnancies who do not
require insulin treatment is still uncertain. In this study, we
investigated whether glucose and insulin levels diﬀer after
the administration of dexamethasone among singleton and
twin pregnancies and in pregnancies with impaired glucose
tolerance (IGT) [6].
2.MaterialsandMethods
Fifty-six women aged between 25 and 35 years old who
received dexamethasone therapy for fetal lung maturation
between 28 and 33 weeks of gestation at the Women’s
Hospital School of the Medicine Zhejiang University from
Jan 2009 to Jan 2011 were recruited into this study. All of2 International Journal of Endocrinology
Table 1: Demographic characteristics (x ±s).
Group Number of
people Age (years) Gestational
age (weeks) BMI
I 22 27.1 ±4.23 0 .4 ±3.12 2 .4 ±3.2
II 18 29.3 ±2.83 1 .2 ±2.42 1 .7 ±2.9
III 16 27.2 ±3.43 2 .8 ±2.72 3 .4 ±2.8
them had received oral glucose tolerance test (OGTT) [6]
between 24 and 28 weeks to screen for gestational diabetes.
Exclusion criteria included gestational hypertension, dia-
betes, renal disorders, and infectious diseases. Patients were
divided into three groups: group I (singleton pregnancies)
22 people, group II (twin pregnancies) 18 people, and group
III (singleton pregnancies with IGT) 16 people. All of the
women gave their informed consent prior to inclusion into
the study, which was approved by the Ethics Committee of
Zhejiang University.
Dexamethasone usage was according to the Guideline
by Obstetrics group of Chinese Medical Association [7];
the women with singleton pregnancies received four doses
of 5mg dexamethasone intramuscularly every 12h; women
with twin pregnancies received six doses of 5mg dexametha-
sone intramuscularly every 8h. Fasting blood samples were
collected before the dexamethasone therapy was commenced
in the morning and 24h, 48h, and 72h after treatment
was completed. Plasma glucose and insulin levels were then
detected.
SPSS 11.5 statistical software was used for statistical
analysis. All data were expressed as mean ± standard
deviation. The F-test was used to determine statistically
signiﬁcantdiﬀerencesbetweenthegroups.AP valueof<0.05
was considered to be statistically signiﬁcant.
3. Results
There was no signiﬁcant diﬀerence in terms of age, ges-
tational weeks, and prepregnancy body mass index (BMI;
Table 1). The blood glucose level in group I was signiﬁcantly
lower than that in groups II and III 24h and 48h after
dexamethasone therapy was started (P<0.01). However,
there was no signiﬁcant diﬀerence before treatment was
started and 72h after treatment (P>0.05; Table 2). The
insulin level in group III was signiﬁcantly higher than that in
groups I and II before treatment was started and 72h after
treatment (P<0.05); 24h and 48h after dexamethasone
therapy, the insulin levels in group I were signiﬁcantly lower
than those in groups II and III (P<0.01). There was no
diﬀerence in the insulin level between groups II and III (P>
0.05; Table 3).
4. Discussion
In this study, we found that the fasting blood glucose levels
24h and 48h after the ﬁrst injection of dexamethasone in
groups II and III were signiﬁcantly higher than those in
group I (P<0.01), but the diﬀerence of blood glucose
Table 2: Blood glucose levels before and after dexamethasone
therapy (x ±s mmol/L).
Group Before treatment 24h 48h 72h
I4 .1 ±1.95 .3 ±2.2
∗ 5.4 ±1.6
∗ 4.9 ±2.1
II 3.8 ±2.26 .9 ±2.57 .3 ±1.94 .7 ±1.9
III 4.2 ±.47 .3 ±2.48 .1 ±3.15 .2 ±2.1
∗Group I compared with group II and group III, ∗P<0.01.
Table 3: Blood insulin levels before and after dexamethasone
therapy (x ±s mmol/L).
Group Before
treatment 24h 48h 72h
I 8.4 ±2.1 45.3 ±
17.2
∗∗
56.2 ±
21.4
∗∗ 6.1 ±2.8
II 9.0 ±3.26 8 .8 ±21.59 8 .3 ±31.98 .2 ±3.0
III 19.2 ±3.4
∗ 76.9 ±22.4 106.1 ±33.12 0 .2 ±4.4
∗
∗Group III compared with group I and group II, ∗P<0.05; ∗∗group I
compared with group II and group III, ∗∗P<0.01.
levels among all three groups either before treatment or
72h afterwards was not signiﬁcant. Since the biologic half-
life of dexamethasone is approximately 36h to 54h [8],
this indicates that blood glucose levels elevation in groups
II and III were consistent with elevated concentration of
dexamethasone after injection.
In twin pregnancies, perhaps due to the enlarged pla-
centa, more insulin antagonistic hormones are secreted,
such as glucocorticoids, placental lactogen, progesterone,
estrogen, and others. In IGT women, exceed insulins were
secreted to maintain normal glucose levels although the
baseline blood glucose level in groups II and III in our study
waswithinthenormalreferencerangebeforedexamethasone
administration. In these groups, insulin secretion by the
pancreatic β-cells was in a “full load” state due to the
increased levels of insulin antagonistic hormones. After
dexamethasone was given to promote fetal lung matura-
tion, insulin resistance increased, which meant that β-cell
secretion was not suﬃcient to oﬀset the insulin antagonistic
hormones. This was the most likely mechanism that led to
the resultant hyperglycemia.
Determination of insulin levels before and after dex-
amethasone injection showed that the insulin levels before
and 72h after the injections in group III were signiﬁcantly
greater than those of groups I and II, which indicated an
increased absolute insulin value and an insulin resistance
state in women with IGT. The blood glucose and the insulin
levels 24h and 48h after dexamethasone administration
in groups II and III were both synchronized with the
corresponding values in group I. Foglia et al. [9] have sug-
gested that dexamethasone has diﬀerent eﬀect on maternal
glucose levels in twin and singleton pregnancies. Within
24h of the ﬁrst corticosteroid injection, twin pregnancies
had a higher average maternal glucose levels than singleton
pregnancies. This may be due to a higher rate of abnormal
glucose tolerance in mothers with twin pregnancies than
singletonpregnancies.Inaddition,Yangetal.[10]foundthatInternational Journal of Endocrinology 3
the use of dexamethasone in the ﬁnal trimester of pregnancy
could increase insulin resistance. Pregnant women with
normal glucose tolerance have normal pancreatic islet β-cell
function. Insulin secretion is increased through enhance-
ment of pancreatic islet β-cell function. Consequently, the
antagonistic eﬀect of dexamethasone is ameliorated, so that
blood glucose levels remain within a normal narrow range.
However, the insulin secretion of pregnant women with
IGT is signiﬁcantly increased under normal circumstances.
Aftertheadministrationofdexamethasone,thesewomenare
unable to compensate for the action of corticosteroids by
enhancing islet β-cellfunction, whichresults in the increased
blood glucose levels.
In conclusion, promoting fetal lung maturation with
dexamethasone aﬀects maternal glucose metabolism. The
degreeofmodiﬁcationofthematernalfastingplasmaglucose
and insulin levels is correlated with the basic maternal
glucose metabolic situation and may correlated with twin
pregnancy status. Consequently, blood glucose levels of twin
pregnancies and those with impaired glucose metabolism
should be closely monitored during the use of dexametha-
sone for fetal lung maturation.
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